Nuvalent, Inc.
NUVL
Classificação em ações
#2080
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Preço da ação
$123.96
Última sincronização: 2026-07-21
Valor de mercado
$9.75B
Variação (1 dia)
0.00%
Variação (1 ano)
36.40%
País
US
Negociar Nuvalent, Inc. (NUVL)
Categoria
Healthcare
Histórico de preços das ações de Nuvalent, Inc. (NUVL)
Preço de fecho mais alto: $123.86 em 2026-07-01
Preço de fecho mais baixo: $18.50 em 2021-07-01
Preço de fecho mais baixo: $18.50 em 2021-07-01
Histórico de preços das ações da Nuvalent, Inc. de 2021 a 2026
Desempenho anual do preço das ações
| Ano | Desempenho |
|---|---|
| 2026 (TTM) | 0.78% |
| 2025 | 19.50% |
| 2024 | 20.56% |
| 2023 | 136.75% |
| 2022 | 51.32% |
| 2021 | 0.00% |
Preço das ações de empresas similares ou concorrentes
| Empresa | Preço da ação | Variação 1a% | País |
|---|---|---|---|
| $536.36 | 25.78% |
US
|
|
| $231.06 | 760.55% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $879.87 | 8.07% |
NL
|
